Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose

Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale (“MADRS”) score reduction from baseline between CYB003 (12mg) vs. placebo (p=0.0005) at 3 weeks

At 6 weeks, incremental MADRS score reductions were seen with 79% of patients in remission from depression after just two doses of CYB003 (12mg)

Favorable safety and tolerability profile with no treatment-related serious adverse events at 12mg and 16mg doses

Company to host CYB003 Topline Depression Study Review and R&D Briefing today at 10:00am ET in New York City

​

https://ir.cybin.com/investors/news/news-details/2023/Cybin-Reports-Positive-Topline-Data-from-Phase-2-Study-of-CYB003-in-Major-Depressive-Disorder-with-79-of-Patients-in-Remission-after-Two-12mg-Doses/default.aspx

submitted by /u/Fmsounermier
[comments]